Investigating how LRRK2 mutations contribute to neurodegeneration in Alzheimer's disease
Official title: Targeting proteostatic mechanisms to inhibit LRRK2-mediated neurodegeneration and neuropathology
Funded at University of Southern California · NIH-11081475 · Data updated 2026-11-12
This study is looking at how changes in the LRRK2 gene might contribute to Alzheimer's and other brain diseases, using brain cells from patients to find out how these changes lead to harmful protein buildup, with the hope of discovering new ways to treat or prevent dementia for those affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project start | April 30, 2024 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $780,220 |
| NIH project number | 7R01NS135607-02 |
| Project ID | NIH-11081475 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with LRRK2 mutations or those diagnosed with Alzheimer's disease and related dementias.
✕Less likely to help
Patients without LRRK2 mutations or those with other forms of dementia unrelated to the mechanisms being studied may not benefit from this research.
What this research studies
This research focuses on understanding the role of LRRK2 mutations in neurodegenerative diseases like Alzheimer's. By studying patient-derived neurons and brain tissue, the researchers aim to uncover how these mutations lead to the accumulation of harmful proteins in the brain. The study will explore the cellular mechanisms involved in protein degradation and how these processes can be targeted for therapeutic interventions. Ultimately, the goal is to identify new treatment strategies that could help manage or prevent dementia associated with LRRK2 mutations.
Why it matters
Potential benefit: If successful, this research could lead to novel therapies that slow down or prevent neurodegeneration in patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in targeting proteostatic mechanisms for neurodegenerative diseases, suggesting that this approach could yield significant insights and advancements.
Where this research is happening
-
University of Southern California
Los Angeles, United States Active
Researchers
- Principal investigator: Hiniker, Annie E — University of Southern California
- Study coordinator: Hiniker, Annie E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.